Group 1 - The company, Heplisav-Bio, announced a financing plan through the placement of new shares, issuing 45,022,000 shares to raise approximately HKD 520 million, with a net amount of about HKD 510 million after expenses [1] - The placement price of the new shares is HKD 11.50, representing a discount of approximately 9.5% compared to the previous trading day's closing price of HKD 12.70, and a discount of about 9.9% compared to the average closing price over the last five trading days [1] - The new shares represent about 5.5% of the existing issued share capital and will account for approximately 5.2% of the enlarged share capital after completion [1] Group 2 - The funds raised will be allocated as follows: approximately HKD 260 million for the development of innovative drug assets, around HKD 200 million for advancing clinical trials of existing pipeline drug assets, and about HKD 50 million for working capital and other general corporate purposes [1] - The issuance is conducted under a general mandate granted at the shareholders' meeting and is expected to be completed on September 5, 2025, or on another date agreed upon in writing with the placement agent [1]
和鉑醫藥 ：通过一般授权配售新股募资约5.2亿港元 药物研发及运营